Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Can perhexiline be utilized without long-term toxicity? A clinical practice audit|
|Citation:||Therapeutic Drug Monitoring, 2016; 38(1):73-78|
|Publisher:||Lippincott Williams & Wilkins|
|Helen Phuong, Bo Y Choi, Cher-Rin Chong, Betty Raman, John D. Horowitz|
|Abstract:||Background: Perhexiline, originally used as a first-line prophylactic antianginal agent, is now regarded primarily as a treatment for otherwise refractory myocardial ischemia. Recent studies have also demonstrated its short-term utility in heart failure, hypertrophic cardiomyopathy, and inoperable aortic stenosis. Its benefits on myocardial energetics state are potentially counter-balanced by risk of hepatotoxicity and peripheral neuropathy during long-term treatment if drug accumulation occurs. Since perhexiline exhibits complex pharmacokinetics with wide inter-individual variability, its long-term use requires regular plasma concentration monitoring. In this study, the risk of neuro- and hepato-toxicity during long-term perhexiline therapy in relation to the intensity of therapeutic drug monitoring was investigated. Furthermore, determinants of mortality during perhexiline treatment were evaluated. Methods: In 170 patients treated with perhexiline for a median of 50 months (interquartile range: 31–94 months), outcomes and relationship to plasma drug concentrations were documented. Results: Rationale for treatment with perhexiline included myocardial ischemia in 88% and severe systolic heart failure in 38%. Plasma concentrations were within the therapeutic range of 150–600 ng/mL on 65% of assay occasions and toxic levels accounted for 8.8% of measurements. No patient developed hepatotoxicity attributable to perhexiline while 3 developed peripheral neuropathy possibly induced by treatment. Actuarial 5-year survival rate was 83% overall, and 76.3% in patients with associated systolic heart failure. Conclusions: This first audit of a large population treated long-term perhexiline demonstrates the following: (1) Although the frequency of monitoring is less than ideal, therapeutic drug monitoring effectively limits occurrence of toxic drug concentrations and virtually eliminates long-term hepato- and neuro-toxicity and (2) Mortality rates during long-term therapy, notably for patients with concomitant heart failure, are surprisingly low.|
|Keywords:||Perhexiline; myocardial energetics; hepatotoxicity; peripheral neuropathy; safety|
|Rights:||Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.|
|Appears in Collections:||Medicine publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.